日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation

皮肤炎症中局部 JAK1 和 JAK2 抑制的临床前评估

Jordan S Fridman, Peggy A Scherle, Robert Collins, Timothy Burn, Claire L Neilan, Denise Hertel, Nancy Contel, Patrick Haley, Beth Thomas, Jack Shi, Paul Collier, James D Rodgers, Stacey Shepard, Brian Metcalf, Gregory Hollis, Robert C Newton, Swamy Yeleswaram, Steven M Friedman, Kris Vaddi

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

选择性 JAK1/2 抑制剂 INCB018424 的临床前表征:对治疗骨髓增生性肿瘤的治疗意义

Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S Fridma

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050

选择性抑制 JAK1 和 JAK2 对啮齿动物关节炎模型有效:INCB028050 的临床前表征

Jordan S Fridman, Peggy A Scherle, Robert Collins, Timothy C Burn, Yanlong Li, Jun Li, Maryanne B Covington, Beth Thomas, Paul Collier, Margaret F Favata, Xiaoming Wen, Jack Shi, Ryan McGee, Patrick J Haley, Stacey Shepard, James D Rodgers, Swamy Yeleswaram, Greg Hollis, Robert C Newton, Brian Metca

Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction

通过有机催化 aza-Michael 反应对 Janus 激酶抑制剂 INCB018424 进行对映选择性合成

Qiyan Lin, David Meloni, Yongchun Pan, Michael Xia, James Rodgers, Stacey Shepard, Mei Li, Laurine Galya, Brian Metcalf, Tai-Yuen Yue, Pingli Liu, Jiacheng Zhou